结直肠癌林奇综合征通用免疫组化检测的系统综述与荟萃分析
该系统综述与荟萃分析纳入56项研究、58,580例结直肠癌,评估通用MMR免疫组化检测 outcomes。MMRd检出率为6.22%,MMR胚系致病性变异为2.00%;年龄、诊断完整性及类型影响检出比例。完整诊断可解释几乎全部MMRd,减少后续多基因 panel 检测。
要点
- MMRd检出率6.22%,MMR胚系PV为2.00%。
- 诊断完整性影响胚系PV比例(1.80%-7.27%)。
- 完整诊断可解释几乎全部MMRd病例。
核心结论
- 年龄、诊断完整性及类型影响MMR胚系PV和不明原因MMRd的比例。
- 完整诊断可解释几乎全部MMRd结直肠癌,减少后续多基因panel检测。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid Medline、Embase和Cochrane CENTRAL至2020年3月20日。
- 纳入56项研究,共58,580例结直肠癌,报告通用MMR免疫组化及胚系分析。
主要发现
- MMRd检出率为6.22%(95% CI 5.08%-7.61%;I²=96%)。
- MMR胚系致病性变异为2.00%(95% CI 1.59%-2.50%;I²=92%),范围1.80%-7.27%。
- 免疫组化结果缺失11.81%,合格患者中76.30%进行了胚系检测。
- 7项研究(6848例完成全部诊断阶段)中,胚系PV为3.01%,双等位体细胞MMR失活为1.75%,不明原因MMRd为0.61%。
临床怎么用
- 结直肠癌通用MMR免疫组化检测可识别林奇综合征患者及亲属。
- 完整诊断流程有助于优化MMRd结直肠癌患者及亲属的检测与监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lynch syndrome is a form of hereditary colorectal cancer (CRC) caused by pathogenic germline variants (PV) in DNA mismatch repair (MMR) genes. Currently, many Western countries perform universal immunohistochemistry testing on CRC to increase the identification of Lynch syndrome patients and their relatives. For a clear understanding of health benefits and costs, data on its outcomes are required: proportions of Lynch syndrome, sporadic MMR-deficient (MMRd) cases, and unexplained MMRd cases. METHODS: Ovid Medline, Embase, and Cochrane CENTRAL were searched for studies reporting on universal MMR immunohistochemistry, followed by MMR germline analysis, until March 20, 2020. Proportions were calculated, subgroup analyses were performed based on age and diagnostics used, and random effects meta-analyses were conducted. Quality was assessed using the Joanna Briggs Critical Appraisal Tool for Prevalence Studies. RESULTS: Of 2723 identified articles, 56 studies covering 58,580 CRCs were included. In 6.22% (95% CI, 5.08%-7.61%; I2 = 96%) MMRd was identified. MMR germline PV was present in 2.00% (95% CI, 1.59%-2.50%; I2 = 92%), ranging from 1.80% to 7.27% based on completeness of diagnostics and age restriction. Immunohistochemistry outcomes were missing in 11.81%, and germline testing was performed in 76.30% of eligible patients. In 7 studies, including 6848 CRCs completing all diagnostic stages, germline PV and biallelic somatic MMR inactivation were found in 3.01% and 1.75%, respectively; 0.61% remained unexplained MMRd. CONCLUSIONS: Age, completeness, and type of diagnostics affect the percentage of MMR PV and unexplained MMRd percentages. Complete diagnostics explain almost all MMRd CRCs, reducing the amount of subsequent multigene panel testing. This contributes to optimizing testing and surveillance in MMRd CRC patients and relatives.
引用
- Eikenboom EL, van der Werf-'t Lam AS, Rodríguez-Girondo M, et al. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. Clin Gastroenterol Hepatol. 2021. PMID: 33887476. doi:10.1016/j.cgh.2021.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。